CCR5 antagonists: 3-(pyrrolidin-1-yl)propionic acid analogues with potent anti-HIV activity

被引：17
作者：
Lynch, CL
Hale, JJ
Budhu, RJ
Gentry, AL
Finke, PE
Caldwell, CG
Mills, SG
MacCoss, M
Shen, DM
Chapman, KT
Malkowitz, L
Springer, MS
Gould, SL
DeMartino, JA
Siciliano, SJ
Cascieri, MA
Carella, A
Carver, G
Karen, H
Schleif, WA
Danzeisen, R
Hazuda, D
Kessler, J
Lineberger, J
Miller, M
Emini, E
机构：
[1] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Immunol Res, Rahway, NJ 07065 USA
[3] Merck Res Labs, Dept Antiviral Res, W Point, PA 19486 USA
来源：
ORGANIC LETTERS | 2003年 / 5卷 / 14期
关键词：
D O I：
10.1021/ol034707c
中图分类号：
O62 [有机化学];
学科分类号：
070303 ; 081704 ;
摘要：
graphic A novel approach to alpha,alpha-disubstituted-beta-amino acids (beta(2,2)-amino acids) was employed in the synthesis of a series of 3-(pyrrolidin-1-yl)-propionic acids possessing high affinity for the CCR5 receptor and potent anti-HIV activity. The rat pharmacokinetics for these new analogues featured higher bioavailabilities and lower rates of clearance as compared to cyclopentane 1.
引用
收藏
页码：2473 / 2475
页数：3
相关论文
共 50 条
  • [21] Discovery of potent human CCR5 antagonists for the treatment of HIV-1 infection - III.
    Finke, PE
    Oates, B
    Meurer, LC
    MacCoss, M
    Mills, SG
    Malkowitz, L
    Springer, MS
    Schleif, WA
    Carella, A
    Carver, G
    Holmes, K
    Emini, EA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U24 - U24
  • [22] Discovery of potent human CCR5 antagonists for the treatment of HIV-1 infection - II.
    Meurer, LC
    Finke, PE
    Oates, B
    MacCoss, M
    Mills, SG
    Malkowitz, L
    Springer, MS
    Schleif, WA
    Carella, A
    Carver, G
    Holmes, K
    Emini, EA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U24 - U24
  • [23] Discovery of potent human CCR5 antagonists for the treatment of HIV-1 infection - IV.
    Caldwell, CG
    Chen, P
    Donnelly, KF
    Finke, PE
    Shankaran, K
    Meurer, LC
    Oates, B
    MacCoss, M
    Mills, SG
    Malkowitz, L
    Springer, MS
    Carella, A
    Carver, G
    Holmes, K
    Emini, EA
    Schleif, WA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U24 - U24
  • [24] Discovery of potent human CCR5 antagonists for the treatment of HIV-1 infection - I.
    Dorn, CP
    Finke, PE
    Oates, B
    Budhu, RJ
    Caldwell, CG
    MacCoss, M
    Mills, SG
    Malkowitz, L
    Springer, MS
    Schleif, WA
    Carella, A
    Carver, G
    Holmes, K
    Emini, EA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U23 - U23
  • [25] In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and Anti-HIV activity of aplaviroc
    Demarest, James F.
    Sparks, Sara S.
    Schell, Kathleen
    Shibayama, Shiro
    McDanal, Charlene B.
    Fang, Lei
    Adkison, Kimberly K.
    Shachoy-Clark, Anne
    Piscitelli, Stephen C.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (10) : 1179 - 1188
  • [26] Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity
    Xue, Chu-Biao
    Chen, Lihua
    Cao, Ganfeng
    Zhang, Ke
    Wang, Anlai
    Meloni, David
    Glenn, Joseph
    Anand, Rajan
    Xia, Michael
    Kong, Ling
    Huang, Taisheng
    Feng, Hao
    Zheng, Changsheng
    Li, Mei
    Galya, Laurine
    Zhou, Jiacheng
    Shin, Niu
    Baribaud, Fredric
    Solomon, Kim
    Scherle, Peggy
    Zhao, Bitao
    Diamond, Sharon
    Emm, Tom
    Keller, Douglas
    Contel, Nancy
    Yeleswaram, Swamy
    Vaddi, Kris
    Hollis, Gregory
    Newton, Robert
    Friedman, Steven
    Metcalf, Brian
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (09): : 483 - 487
  • [27] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
    Baba, M
    Nishimura, O
    Kanzaki, N
    Okamoto, M
    Sawada, H
    Iizawa, Y
    Shiraishi, M
    Aramaki, Y
    Okonogi, K
    Ogawa, Y
    Meguro, K
    Fujino, M
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) : 5698 - 5703
  • [28] (E)-3-[2,5-Dioxo-3-(propan-2-ylidene)pyrrolidin-1-yl]acrylic acid
    Miao, Fang
    Qin, Bao-Fu
    Yang, Li-Zhen
    Yang, Xin-Juan
    Zhou, Le
    ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2010, 66 : O634 - U5171
  • [29] Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs
    Nakata, Hirotorno
    Steinberg, Seth M.
    Koh, Yasuhiro
    Maeda, Kenji
    Takaoka, Yoshikazu
    Tarnarnura, Hirokazu
    Fujii, Nobutaka
    Mitsuya, Hiroaki
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (06) : 2111 - 2119
  • [30] Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists
    Ernst, Justin
    Dahl, Russell
    Lum, Christopher
    Sebo, Lubomir
    Urban, Jan
    Miller, Stephen G.
    Lundstroem, Jan
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (04) : 1498 - 1501
12345